CHA2DS2-VASc and HAS-BLED scores are not associated with cardiac defibrillators therapies

Basit Öğe Kaydı
dc.contributor.authorAlsancak, Yakup
dc.contributor.authorSari, Hasan
dc.contributor.authorGurbuz, Ahmet Seyfeddin
dc.contributor.authorSertdemir, Ahmet Lutfi
dc.contributor.authorAribas, Alpay
dc.contributor.authorSoylu, Ahmet
dc.date.accessioned2024-02-23T14:34:53Z
dc.date.available2024-02-23T14:34:53Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractAim: The CHA(2)DS(2)-VASc (heart failure, hypertension, age >75, diabetes mellitus, stroke history, vascular disease, 65-74 age range, gender) and HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history, labile INR, elderly, drugs/alcohol) are scoring system for using to estimate stroke and bleeding development in cases with atrial fibrillation. We aim to evaluate the relationship between the implantable cardioverter defibrillator (ICD) therapies and CHAIDSi-VASc and HAS-BLED scores. Methods: 398 patients were included in this retrospective study after reviewing the data of the patients above the age of 18 who had ICD implantation for any reason between 2014-2019 and who were found to have at least two pacemaker check-ups with 6-month intervals. CHA(2)DS(2)-VASc and HAS-BLED scores were calculated during the device implantation and last control visit date. Results: 148 of the patients received ICD therapy (appropriate shock [n = 1181 and in appropriate therapy In = 301) and 250 of them did not receive any therapy. It was observed that the CHA(2)DS(2)-VASc and HAS-BLED scores were similar in the groups receiving and not receiving therapy (respectively, p = 0.64 and p = 0.60). CHA(2)DS(2)-VASc and HAS-BLED scores were similar in patients with appropriate shock or not (respectively p = 0.89 and p = 0.85) with median follow-up period 5.5 years. Multivariate regression analysis showed that reduced ejection fraction, presence of single-chamber ICD, lapsing of a long time after the implantation were independent risk factors for ICD device therapies (p < 0.05). Conclusions: CHA(2)DS(2)-VASc and HAS-BLED scores are not associated with device-based ICD therapies.en_US
dc.identifier.doi10.33678/cor.2021.058
dc.identifier.endpage311en_US
dc.identifier.issn0010-8650
dc.identifier.issn1803-7712
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85111521560en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage304en_US
dc.identifier.urihttps://doi.org/10.33678/cor.2021.058
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15789
dc.identifier.volume63en_US
dc.identifier.wosWOS:000742851900002en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCzech Soc Cardiology & Czech Soc Cardiovascular Surgeryen_US
dc.relation.ispartofCor Et Vasaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCha(2)Ds(2)-Vascen_US
dc.subjectHas-Bleden_US
dc.subjectIcden_US
dc.subjectShocken_US
dc.subjectTherapyen_US
dc.titleCHA2DS2-VASc and HAS-BLED scores are not associated with cardiac defibrillators therapiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu